Sign In
to Vote &
Create Storyboards.
 
Could Gilead Stock Get A Boost From Inhaled Remdesivir? Gilead has indicated that it would be starting clinical trials for an inhaled version of Remdesivir shortly. While the wide-spectrum anti-viral drug is currently given intravenously for severe cases of Covid-19 in the hospital, the new delivery method could enable treatment at earlier stages of...
3
0
0


Storyboard
Print
Share this Article



Comment on this Article

Please Sign In to comment

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard